Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-LGI1 Antibody (R1G79)

Catalog #:   RHB80704 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: IHC, IP, WB
Accession: O95970
Overview

Catalog No.

RHB80704

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

IHC: 1:100-1:200, IP: 1:20-1:50, WB: 1:1000-1:2000

Target

EPT, Leucine-rich glioma-inactivated protein 1, LGI1, Epitempin-1

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O95970

Applications

IHC, IP, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R1G79

Data Image
  • Immunoprecipitation
    Immunoprecipitate (IP) analysis using the Antibody at 1:50 dilution. (wb at 1:3K dilution)
  • Western blot
    Western blot analysis of Lgi1 expression in HeLa cell lysate.
  • Western blot
    All lanes use the Antibody at 1:1k dilution for 1 hour at room temperature.
References

Leucine-rich glioma-inactivated 1 (LGI-1) autoimmune encephalitis presenting as reversible cerebral vasoconstriction syndrome: Initial case report from India., PMID:40488299

Clinical Characteristics and Seizure Outcomes in Antibody-Positive Autoimmune Limbic Encephalitis., PMID:40463859

Biallelic LGI1 and ADAM23 variants cause hippocampal epileptic encephalopathy via the LGI1-ADAM22/23 pathway., PMID:40455867

Paraneoplastic LGI1 Encephalitis Associated with Lung Adenocarcinoma: A Case Report., PMID:40407616

[Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis diagnosed from T1 signal intensity changes in basal ganglia: a case report and literature review]., PMID:40399057

Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (II): Antibodies to Surface Antigens., PMID:40393020

Clinical, Electroencephalogram and Imaging Characteristics of Patients With Anti-LGI1 Antibody Encephalitis: A Multicenter Cohort Study., PMID:40322833

Comparison of commercial and in-house tissue-based and cell-based assays for the detection of autoantibodies targeting neuronal surface proteins: a prospective cohort study., PMID:40303411

Multimodal prognostication of autoimmune encephalitis: an Australian autoimmune encephalitis consortium study., PMID:40281286

Neurodegeneration and the immune system: lessons from autoimmune encephalitis., PMID:40274643

Rituximab for Leucine-Rich Glioma-Inactivated 1 (LGI1) Antibody-Related Super-refractory Status Epilepticus: A Case Report and Literature Review., PMID:40271344

Successful treatment of morvan syndrome with efgartigimod: report of two cases., PMID:40268813

From immunobiology to intervention: Pathophysiology of autoimmune encephalitis., PMID:40267699

Electroencephalographic biomarkers of antibody-mediated autoimmune encephalitis., PMID:40206289

Long-Term Seizure Outcomes in Autoimmune Encephalitis., PMID:40182605

Leucine-rich glioma-inactivated protein 1 antibody-positive limbic encephalitis in a patient with an early-stage asymptomatic breast cancer., PMID:40180343

Neuroglia in autoimmune encephalitis., PMID:40148042

Intravenous immunoglobulin as first-line acute treatment in adults with autoimmune encephalitis caused by antibodies to NMDAR, LGI1 and CASPR2., PMID:40131535

Current and emerging therapies for autoimmune encephalitis., PMID:40125911

Retrograde Amnesia in LGI1 and CASPR2 Limbic Encephalitis: Two Case Reports and a Systematic Literature Review., PMID:40116573

Activated αβ T- and reduced mucosa-associated invariant T cells in LGI1- and CASPR2-encephalitis., PMID:40094812

Prevalence, clinical profiles, and prognosis of Isaacs syndrome: A nationwide survey study in Japan., PMID:40058033

Microglial Activation Visualized by [18F]-DPA714 PET Is a Potential Marker of Severity and Prognosis for Anti-LGI1 Encephalitis., PMID:40052391

Clinical, radiological, pathological and prognostic features of general paresis: a cohort study., PMID:40036706

A Case of Anti-LGI1 Limbic Encephalitis Presenting With Non-convulsive Status Epilepticus and Requiring a Long Period of Hospitalization., PMID:40007925

Capturing what matters: Patient-reported LGI1-ANTibody encephalitis outcome RatiNg scale (LANTERN)., PMID:39996410

Abnormal CSF-Specific OCBs in Neuronal Surface Antibody-Associated Autoimmune Encephalitis Differentiating from Viral Encephalitis., PMID:39991667

GAD antibodies in neurological disease: a critical evaluation of the utility and treatment implications of GAD antibodies in clinical practice., PMID:39985693

Distinctive seizure signature in the first video case-control study of a naturally-occurring feline autoimmune encephalitis model., PMID:39984138

Patient-derived monoclonal LGI1 autoantibodies elicit seizures, behavioral changes and brain MRI abnormalities in rodent models., PMID:39984135

Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus., PMID:39965877

Enigmatic intractable Epilepsy patients have antibodies that bind glutamate receptor peptides, kill neurons, damage the brain, and cause Generalized Tonic Clonic Seizures., PMID:39932550

Autoimmune Encephalitis., PMID:39893022

Hippocampal dysfunction after autoimmune encephalitis depending on the antibody type., PMID:39891731

Update on autoimmune dementia and its precursors., PMID:39889830

Cognitive Deficits in Anti-LGI1 Encephalitis Are Linked to Immunotherapy-Resistant White Matter Network Changes., PMID:39879565

Rare mixed dementia: A case report., PMID:39876884

Acute Hyperhidrosis: A Clue to Underlying Autonomic Dysfunction and a Rare Neurological Disorder., PMID:39867015

Varied Clinical Features and Outcomes of Autoimmune Encephalitis: A Retrospective Case Series., PMID:39866989

Autoimmune encephalitis: recovery, residual symptoms and predictors of long-term sequelae., PMID:39832911

Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review., PMID:39820999

Diagnostic utility of magnetic resonance imaging in autoimmune encephalitis: prognostic implications., PMID:39764590

Identifying Key Prognostic Indicators for Relapse and Chronic Epilepsy in Autoimmune Encephalitis: Insights from a Multicenter Retrospective Study., PMID:39735892

LGI1 encephalitis manifesting as a delayed paraneoplastic response of squamous cell lung cancer on remission., PMID:39734683

Recent advances in autoimmune encephalitis., PMID:39706227

Acute Bilateral Vocal Cord Paralysis in a Patient With Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Limbic Encephalitis., PMID:39664290

Anti-LGI1 Autoimmune Limbic Encephalitis: An Easy-To-Miss Diagnosis., PMID:39651393

Efficacy of ofatumumab combined with corticosteroids in the treatment of autoimmune encephalitis: a 6-month cohort study., PMID:39602016

Clinical characteristics and prognosis analysis of acute symptomatic seizures secondary to autoimmune encephalitis., PMID:39539648

Clinical Features and Electroencephalogram Analysis of Brain Network Functional Connectivity in Anti-Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis., PMID:39494201

Datasheet

Document Download

Anti-LGI1 Antibody (R1G79).pdf

 

$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-LGI1 Antibody (R1G79) [RHB80704]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only